Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
about
Saturated fat, carbohydrate, and cardiovascular diseaseFenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemiaAtherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspectsHypertriglyceridemia influences the degree of postprandial lipemic response in patients with metabolic syndrome and coronary artery disease: from the CORDIOPREV study.LDL phenotype in subjects with mild cognitive impairment and Alzheimer's disease.Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome.Association of Plasma Ghrelin Levels with Insulin Resistance in Type 2 Diabetes Mellitus among Saudi Subjects.Atherogenic dyslipidemia and cardiovascular risk factors in obese childrenDyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentTreating the metabolic syndrome.Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort)Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trialsStudy of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease.Arterial Thickness and Immunometabolism: The Mediating role of Chronic Exercise.Leu72Met and Other Intronic Polymorphisms in the GHRL and GHSR Genes Are Not Associated with Type 2 Diabetes Mellitus, Insulin Resistance, or Serum Ghrelin Levels in a Saudi Population.Protective effect of Clerodendron glandulosum extract against experimentally induced metabolic syndrome in rats.Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.Impaired capsaicin-induced relaxation of coronary arteries in a porcine model of the metabolic syndrome.Antihyperlipidemic effect of fisetin, a bioflavonoid of strawberries, studied in streptozotocin-induced diabetic rats.GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly.Beneficial Effects of Phyllanthus amarus Against High Fructose Diet Induced Insulin Resistance and Hepatic Oxidative Stress in Male Wistar Rats.Determinants of female sexual dysfunction in type 2 diabetes.Abdominal obesity and cardiometabolic risk in children and adolescents, are we aware of their relevance?
P2860
Q24646194-9DB4D8D8-D6EE-4B50-9BE9-396608A13AACQ28284661-B997F4B9-200A-4B25-BD65-FC01A924BE6DQ28546605-0B95B685-83EE-433E-9531-FC2738D4E64CQ33572736-784618FF-202E-4205-A723-D61ADC3E2AADQ33846928-7C5FB9AA-7E62-4D60-ABAA-21801F1D49C9Q33847586-19B0910C-D276-47BD-A542-C5565241E8F4Q33889867-AA0EB910-232C-441C-A1B5-C97DB23D3238Q34461856-C571A4B2-E354-456A-984A-5D41141A1CC3Q35029623-3B145D90-1B97-455D-920F-E5CA210CC219Q36815978-FE1587FC-DBDF-4983-9D25-104376ACB042Q36906018-A372F482-1AA6-435F-84E9-D5393FF2FC9DQ37122213-F08ECD8D-FD23-49A4-9D49-010F2BF4ED80Q37364089-8ACB221B-95A3-4D90-B6A9-04E1AD845816Q37670674-D1BD5A0A-E8FC-4413-B279-ADAFECA83991Q38714345-AB9BB29B-0CC0-4525-9D0D-82F6F677A568Q41964148-01AB888C-6910-4BDC-90BC-4E6D49043FD2Q42906730-B2C55591-E7F6-4791-9B92-1FB342F3104CQ46372426-5B353611-6017-414F-A2D7-ED221D5B3F06Q46662826-5756DDC0-5C8D-44A1-BF68-3186EE676D1DQ50468419-B68DB40B-843E-4C4E-8216-545113C2EC7BQ50951023-75B8B66E-9839-4FF6-98A2-B8D3554B30D1Q51082217-A3EFA625-0AB6-43B5-B89C-338CAE3CB736Q51572713-85639C37-311D-4256-967A-5BCB84393701Q57825533-3D8EBD7E-1186-4DDE-9645-0B1CDE7A9664
P2860
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
@ast
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
@en
type
label
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
@ast
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
@en
prefLabel
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
@ast
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
@en
P921
P1433
P1476
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
@en
P2093
Scott M Grundy
P356
10.1016/S1098-3597(06)80005-0
P478
P577
2006-01-01T00:00:00Z